Literature DB >> 31628515

Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?

Sandip Basu1,2, Rahul V Parghane3,4, Sharmila Banerjee3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31628515     DOI： 10.1007/s00259-019-04546-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  12 in total

1.  The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios.

Authors:  Sandip Basu; Vikas Ostwal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-20       Impact factor: 9.236

2.  Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?

Authors:  Sandip Basu; Rahul V Parghane; Vikas Ostwal; Shailesh V Shrikhande
Journal:  Nucl Med Commun       Date:  2018-01       Impact factor: 1.690

3.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Authors:  Linda Villard; Anna Romer; Nicolas Marincek; Philippe Brunner; Michael T Koller; Christian Schindler; Quinn K T Ng; Helmut R Mäcke; Jan Müller-Brand; Christoph Rochlitz; Matthias Briel; Martin A Walter
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

4.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers.

Authors:  Anna Imhof; Philippe Brunner; Nicolas Marincek; Matthias Briel; Christian Schindler; Helmut Rasch; Helmut R Mäcke; Christoph Rochlitz; Jan Müller-Brand; Martin A Walter
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Authors:  David L Bushnell; Thomas M O'Dorisio; M Sue O'Dorisio; Yusuf Menda; Rodney J Hicks; Eric Van Cutsem; Jean-Louis Baulieu; Francoise Borson-Chazot; Lowell Anthony; Al B Benson; Kjell Oberg; Ashley B Grossman; Mary Connolly; Hakim Bouterfa; Yong Li; Katherine A Kacena; Norman LaFrance; Stanislas A Pauwels
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

Authors:  J B Cwikla; A Sankowski; N Seklecka; J R Buscombe; A Nasierowska-Guttmejer; K G Jeziorski; R Mikolajczak; D Pawlak; K Stepien; J Walecki
Journal:  Ann Oncol       Date:  2009-10-15       Impact factor: 32.976

7.  Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.

Authors:  E Seregni; M Maccauro; C Chiesa; L Mariani; C Pascali; V Mazzaferro; F De Braud; R Buzzoni; M Milione; A Lorenzoni; A Bogni; A Coliva; S Lo Vullo; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02       Impact factor: 9.236

8.  High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.

Authors:  Grace Kong; Jason Callahan; Michael S Hofman; David A Pattison; Tim Akhurst; Michael Michael; Peter Eu; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-09-27       Impact factor: 9.236

9.  Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Authors:  Jolanta Kunikowska; Leszek Królicki; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Anna Sowa-Staszczak; Dariusz Pawlak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

10.  Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.

Authors:  S Vinjamuri; T M Gilbert; M Banks; G McKane; P Maltby; G Poston; H Weissman; D H Palmer; J Vora; D M Pritchard; D J Cuthbertson
Journal:  Br J Cancer       Date:  2013-03-14       Impact factor: 7.640
View more
  3 in total

Review 1.  A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

Authors:  Rubel Chakravarty; Sudipta Chakraborty
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

Review 2.  One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.

Authors:  Sandip Basu; Sudipta Chakraborty; Rahul V Parghane; Rohit Ranade; Pradeep Thapa; Ramesh V Asopa; Geeta Sonawane; Swapna Nabar; Hemant Shimpi; Ashok Chandak; K V Vimalnath; Vikas Ostwal; Anant Ramaswamy; Manish Bhandare; Vikram Chaudhari; Shailesh V Shrikhande; Bhawna Sirohi; Ashutosh Dash; Sharmila Banerjee
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25

Review 3.  Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology.

Authors:  Christine Rangger; Roland Haubner
Journal:  Pharmaceuticals (Basel)       Date:  2020-01-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.